ENLIVEX LTD

Enlivex’s stock plunged 9.82%, dropping from a 52‑week high of $27.15 to under $0.20. Learn why its unproven biotech pipeline and thin liquidity spell risk for investors.

Enlivex’s 0.98% rise is a quiet caution: low liquidity, no clinical progress, and a $4.1M cap leave investors wary of speculative gains.

Enlivex Therapeutics (ENLV) edges up 0.98%, trading at $0.22 with a $4.1M market cap, amid a 70% month‑end drop and 24‑hour peer shifts.